Doxifluridine

Summary

Doxifluridine (CHEMBL1130) is a phase-3 clinical-stage small-molecule antineoplastic agent; indicated across 1 condition including gastric neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 3
• Chemistry: 246.19 Da · C9H11FN2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1130
Name	Doxifluridine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	18343
ChEBI	CHEBI:31521
Molecular formula	C9H11FN2O5
Molecular weight	246.19
InChIKey	ZWAOHEXOSAUJHY-ZIYNGMLESA-N

SMILES: C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O

IUPAC name: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoropyrimidine-2,4-dione

ChEBI definition: A pyrimidine 5’-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5’ position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.

Pharmacological roles (ChEBI): antineoplastic agent, prodrug.

Other ChEBI roles (chemical / environmental): antimetabolite.

Also known as: Capecitabine related compound b, Doxifluridina, Doxifluridine, Flutron, Fulturon, Furtulon, NSC-758890, RO 219738, RO-219738, SID29215154, SID50106323, SID56322615

Patent coverage: 13,654 distinct patent families (55,226 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 55,219 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Microtubule-associated protein tau, Prelamin-A/C, Inositol monophosphatase 1, Peripheral myelin protein 22.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	6.25	Potency	562.3	nM	CHEMBL_ACT_3655664
LMNA	5.95	Potency	1122	nM	CHEMBL_ACT_3626240
MAPT	5.5	Potency	3162	nM	CHEMBL_ACT_4059669

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastric neoplasm	3	MONDO:0021085	MONDO:0001056

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01401075	PHASE4	COMPLETED	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
NCT00296322	PHASE3	COMPLETED	Trial of Adjuvant Chemotherapy for Gastric Cancer
NCT00296335	PHASE3	COMPLETED	Trial of Adjuvant Chemotherapy for Gastric Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).